Prostacyclin for pulmonary arterial hypertension

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Respiratory Medicine

Background:

• Pulmonary arterial hypertension (PAH) is a severe condition characterized by elevated pulmonary artery pressures, leading to right heart failure and death.
• Prostacyclin and its analogues are vasodilators that can reverse vascular remodeling in PAH.
• While effective, traditional prostacyclin administration (intravenous) carries risks; newer formulations offer improved safety profiles.

Purpose of the Study:

• To evaluate the efficacy and safety of prostacyclin, its analogues, and receptor agonists in treating adult and pediatric PAH.
• To compare different administration routes (intravenous, subcutaneous, oral, inhaled) and novel agents like selexipag.

Main Methods:

• Systematic review and meta-analysis of randomized controlled trials (RCTs) identified through comprehensive database searches.
• Included RCTs compared prostacyclin-based therapies against control groups for at least six weeks.
• Primary outcomes assessed included World Health Organization (WHO) functional class, six-minute walk distance (6MWD), and mortality.

Main Results:

• Intravenous prostacyclin significantly improved WHO functional class, 6MWD, and reduced mortality, though with increased adverse events.
• Inhaled prostacyclin showed benefits in function and hemodynamics, but mortality effects were uncertain.
• Oral prostacyclins had less certain effects, while selexipag demonstrated reduced clinical worsening and increased adverse events, with uncertain survival impact.

Conclusions:

• Intravenous prostacyclin offers clear benefits for PAH patients, but necessitates careful management of adverse events.
• Inhaled prostacyclins provide moderate benefits, while oral formulations and selexipag require further investigation regarding long-term efficacy and safety.
• Real-world data may further elucidate the clinical effectiveness of these therapies in PAH management.